Intellia, Holder of Rights to UC’s CRISPR Technology, to Win China Patent – Genetic Engineering & Biotechnology News
|
Intellia, Holder of Rights to UC's CRISPR Technology, to Win China Patent
Genetic Engineering & Biotechnology News Intellia Therapeutics, said today it received notice from China's State Intellectual Property Office (SIPO) that it will grant the company a broad patent covering CRISPR/Cas9 single-guide gene editing methods and compositions. CRISPR stands for … BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China Intellia Therapeutics Announces Patent for CRISPR/Cas Genome … CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China |
